LPL Financial
CCCC icon

LPL Financial’s C4 Therapeutics CCCC Stock Holding History

LPL Financial’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Buy
253,165
+6,365
+3% +$21.8K ﹤0.01% 4284
2026
Q1 		$649K Buy
246,800
+3,495
+1% +$8.23K ﹤0.01% 4540
2025
Q4 		$465K Buy
243,305
+42,375
+21% +$100K ﹤0.01% 4783
2025
Q3 		$446K Buy
200,930
+4,675
+2% +$11.2K ﹤0.01% 4719
2025
Q2 		$281K Buy
196,255
+2,345
+1% +$3.41K ﹤0.01% 4821
2025
Q1 		$310K Buy
193,910
+123,585
+176% +$369K ﹤0.01% 4549
2024
Q4 		$253K Buy
70,325
+8,150
+13% +$40.5K ﹤0.01% 4663
2024
Q3 		$354K Buy
62,175
+40,075
+181% +$241K ﹤0.01% 4292
2024
Q2 		$102K Buy
+22,100
New +$132K ﹤0.01% 4740

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial's CCCC Position: Q2 2026 in Review

LPL Financial increased its C4 Therapeutics (CCCC) stake by 2.6% in Q2 2026, buying an estimated $21.8K and bringing the position to 253,165 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4284.

LPL Financial first reported a position in CCCC in Q2 2024 and has held it in 9 quarters since. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • LPL Financial held 253,165 shares of C4 Therapeutics worth $1.18M as of Q2 2026.
  • LPL Financial bought 6,365 C4 Therapeutics shares in Q2 2026, an estimated $21.8K.
  • C4 Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #4284 holding.
  • LPL Financial first reported a position in C4 Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.